FGFR4 G636C

CI-VAR-00001776Explore in graph →CIViC 3215

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Gastric Neoplasm1
FGFR4 G636C	FGFR Inhibitor ASP5878	Predictive	D	Supports Sensitivity Response	3	submitted	EID8905 Identification of an oncogenic mutation in FGFR4 in a human gastric tumour that leads to constitutive activation and sensitivity to ASP5878. PMID 31601997 · Futami et al., 2019 · Open in CIViC	civic
Unmapped disease1unmapped disease
FGFR4 G636C	(functional)	Functional	D	Supports Gain Of Function	4	submitted	EID10092 The FGFR4 G636C mutation was found in a human gastric tumour. NIH/3T3 cells were transduced with WT or mutant (G636C) FGFR4. Levels of autophosphorlyation was much higher in the mutant cells. Transduc… (full text at CIViC) PMID 31601997 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.